A carregar...
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells
Combination treatment is a promising strategy to improve prognosis of hepatocellular carcinoma (HCC). Sorafenib is a traditional first-line agent approved for the treatment of advanced HCC, though with limited efficacy. Previously, we reported that lonafarnib, an orally bioavailable non-peptide inhi...
Na minha lista:
| Publicado no: | Aging (Albany NY) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710066/ https://ncbi.nlm.nih.gov/pubmed/31409760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.102165 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|